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Semen inhibits Zika virus infection of cells
and tissues from the anogenital region
Janis A. Müller1, Mirja Harms1, Franziska Krüger1, Rüdiger Groß 1, Simone Joas1, Manuel Hayn1,
Andrea N. Dietz2, Sina Lippold 2, Jens von Einem2, Axel Schubert2, Manuela Michel2, Benjamin Mayer3,
Mirko Cortese4, Karen S. Jang5,6, Nathallie Sandi-Monroy1, Miriam Deniz7, Florian Ebner7,8, Olli Vapalahti9,10,
Markus Otto11, Ralf Bartenschlager4,12, Jean-Philippe Herbeuval13, Jonas Schmidt-Chanasit14,15,
Nadia R. Roan5,6 & Jan Münch1,16
Zika virus (ZIKV) causes severe birth defects and can be transmitted via sexual intercourse.
Semen from ZIKV-infected individuals contains high viral loads and may therefore serve as an
important vector for virus transmission. Here we analyze the effect of semen on ZIKV
infection of cells and tissues derived from the anogenital region. ZIKV replicates in all ana-
lyzed cell lines, primary cells, and endometrial or vaginal tissues. However, in the presence of
semen, infection by ZIKV and other flaviviruses is potently inhibited. We show that semen
prevents ZIKV attachment to target cells, and that an extracellular vesicle preparation from
semen is responsible for this anti-ZIKV activity. Our findings suggest that ZIKV transmission
is limited by semen. As such, semen appears to serve as a protector against sexual ZIKV
transmission, despite the availability of highly susceptible cells in the anogenital tract and
high viral loads in this bodily fluid.
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Zika virus (ZIKV) was first identified in 1947 in Uganda
1
but was not thought to be a significant threat to humans.
When the virus re-emerged in 2007, however, it rapidly
caused a series of epidemics in Micronesia2, the South Pacific3,
and the Americas4. In March 2017, 64 countries and territories
reported ongoing viral transmission5, primarily through some
species of mosquitoes. ZIKV can cause numerous diseases in
adults, including meningoencephalitis6, myelitis7, and Guillain-
Barré syndrome8. Of even greater concern is the observation that
the ZIKV epidemics were associated with a dramatic increase in
cases of microcephaly in newborns. Several studies revealed that
ZIKV infection during pregnancy can directly cause fetal demise,
microcephaly, and other congenital problems9 and that disease
may develop in up to 46% of the cases10.
Atypical for an arthropod-borne virus, ZIKV has also been
reported to be transmitted via sexual intercourse (reviewed by
refs. 11–15). Up to now, 13 countries reported several cases of
sexual transmission of ZIKV5, resulting in classification of this
virus as a sexually transmitted pathogen. These case reports
describe sexual ZIKV transmission not only by symptomatic but
also by asymptomatic individuals. Semen (SE) from an infected
individual can harbor ZIKV at extremely high concentrations of
up to 108 viral RNA copies per ml16–20 which are 4–5 log-fold
higher than that present in serum, urine, and saliva, and the virus
can remain detectable in SE >6 months after onset of
symptoms20–23. These observations have led to the notion that
ZIKV in SE may be responsible for many cases of viral
transmission16,23–28. As a result, the World Health Organization
has advised males and females with confirmed Zika fever or those
who have traveled to areas with active ZIKV circulation to con-
sider using condoms or staying abstinent for a period of at least
6 months29. However, the true contribution of sexual transmis-
sion to the epidemic spread of ZIKV is currently unclear30. A
recent study estimated the overall sexual ZIKV transmission rate
to be as high as 3%31. This number, however, is based on
mathematical models rather than clinical and epidemiological
data. Whether ZIKV efficiently transmits sexually is of high
importance, because if so, this sexually transmitted disease may
contribute significantly to microcephaly cases. Consistent with
the idea that ZIKV can be sexually transmitted are in vivo
experiments suggesting that vaginal ZIKV exposure of pregnant
mice or mating of ZIKV-infected mice with naive females results
in viral transmission and infection of the fetus32–34 where it
causes malformations or fetal demise35.
During most cases of sexual ZIKV transmission, SE is the viral
vehicle. SE is rich in bioactive organic and inorganic substances,
including proteins, enzymes, polyamines, cytokines, chemokines,
hormones, and ions36. These soluble components can induce
transient changes in the vaginal milieu that may influence the
efficiency of virus transmission37. In the case of human immu-
nodeficiency virus-1 (HIV-1), a virus that is predominantly
transmitted sexually, SE markedly enhances its infectivity38–41.
The HIV-enhancing activity of SE has been attributed to amyloid
fibrils naturally present in SE. These fibrils form by self-assembly
of peptide fragments derived from the seminal proteins prostatic
acid phosphatase (PAP) and semenogelins38–40,42–44. Seminal
amyloid has a positive surface charge that allows it to bind to and
concentrate the negatively charged HIV particles, thereby
increasing their attachment to and viral entry into cellular tar-
gets42,43,45. The best-characterized SE amyloid forms from the
PAP248-286 peptide and is termed semen-derived enhancer of
virus infection (SEVI)38. Several compounds that counteract the
infection-promoting activity of seminal amyloid have been
described and are being considered as leads for microbicide
development46,47. The effect of SE and seminal amyloids on
ZIKV infection has not yet been addressed35,48 but could
contribute to a better understanding of ZIKV as a sexually
transmitted disease30,49.
Since ZIKV is a sexually transmittable pathogen, we studied
whether it replicates in anogenital tissues and whether SE
and seminal amyloid affect ZIKV infection. We show that
ZIKV efficiently replicates in cells and tissues derived from the
anogenital region. Surprisingly, seminal amyloid does not
affect ZIKV infection, while SE markedly suppresses ZIKV
infection through blocking viral attachment to target cells.
These results can help explain the low frequencies of ZIKV
transmission by sexual intercourse despite the high viral loads
detectable in SE and the high susceptibility of anogenital cells to
ZIKV infection.
Results
ZIKV infects and replicates in cells of the anogenital tract. As a
sexually transmitted virus, ZIKV needs to productively infect
cells present at mucosal portals of entry, e.g., the female repro-
ductive tract (FRT) or the rectum. To clarify whether cells of
anogenital origin support productive infection, primary endo-
metrial stromal fibroblasts (eSFs) and human foreskin fibroblasts
(HFFs), as well as cell lines derived from endometrium (HeLa,
TZM-bl), colon (SW480 and T-84), or ovaries (OVCAR-3 and
SKOV3), were inoculated with African ZIKV isolate MR7661.
Two hours postinfection, cells were washed, fresh medium was
added, and 2 days later cells were stained for the viral E protein.
Confocal microscopy demonstrated that all analyzed cell types
were infected as assessed by E protein expression (Fig. 1a). All
infected cells released viral RNA (Fig. 1b) and infectious virus
(Fig. 1c). Among the tested cell lines, viral replication was least
efficient in SKOV3 and T-84 cells and most efficient in SW480,
HeLa, and OVCAR-3 cells. Primary endometrial and foreskin
fibroblasts also both supported efficient levels of ZIKV replica-
tion. These results demonstrate that ZIKV is capable of estab-
lishing productive infection in cells derived from the anogenital
region.
ZIKV replicates in ex vivo endometrial and vaginal tissues. To
analyze whether ZIKV also replicates in intact tissues isolated
from the FRT, surgically removed vaginal (VT) or endometrial
tissue (ET) was cut into tissue blocks and infected with ZIKV, as
previously described for HIV-1 infection experiments50–53. For
these experiments, we used ZIKV MR766 and the recent pan-
demic FB-GWUH-2016 (GWUH) isolate derived from the brain
of an aborted fetus54. After 4 h, tissues were extensively washed to
remove viral inoculum, and six tissue blocks were placed at the
air/liquid interface on gel-foams in 12-well plates. Productive
virus infection was assessed by quantifying infectious progeny
virus in supernatants collected from day 0 (wash control) up to
day 8 postinfection. Titers that increased more than 10-fold as
compared to the wash control were considered indicative of
productive infection. Both ZIKV strains established productive
infection in the majority of the analyzed VTs and ETs (Fig. 2 and
Table 1). The absolute titers and kinetics of replication, however,
varied between experiments and donors. For example, ZIKV
GWUH replicated in 6 out of the 7 VTs (frequency of 86%) with
a maximum titer of 2.32 × 106 tissue culture infectious dose 50
(TCID50)/ml observed at day 8 postinfection for tissue derived
from donor #1 (Fig. 2 and Table 1). ZIKV MR766 established
infection in 66% of VTs (4 out of the 6 tissues) (Fig. 2a and
Table 1) with the highest titer observed at day 4 in tissue from
donor #6. In all seven ET samples analyzed, ZIKV replication was
observed (Fig. 2c, d, Table 1), with the highest titer being 1.6 × 106
TCID50/ml at day 8 with tissue from donor #13.
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To further determine the variability of viral replication in an
individual tissue, a vaginal sample was cut into 48 blocks, and all
blocks were infected in the same tube but analyzed individually in
individual wells of a microtiter plate. As shown in Supplementary
Fig. 1, ZIKV replicated in 66% (32 out of 48) of the blocks. Thus,
although there was considerable variability in these assays, the
results unequivocally demonstrate that ZIKV replicates ex vivo in
VTs and ETs.
Seminal amyloid does not alter ZIKV infection rates. As it has
previously been reported that amyloid fibrils in SE boost HIV-1
infection38–40,42–44, we were interested in whether these fibrils
may exert similar effects on ZIKV. To test this, the two ZIKV
strains were exposed to physiologically relevant concentrations of
SEVI fibrils38. After 5 min, SEVI-treated viruses were added to
Vero E6 cells, which are highly permissive for ZIKV55. Infection
rates were determined 2 days later by a cell-based ZIKV immu-
nodetection assay that quantifies the flavivirus protein E56.
Results shown in Supplementary Fig. 2a demonstrate that SEVI
fibrils had no effect on infection by either ZIKV strain. To ensure
that the SEVI fibrils were active, we next measured the effect of
SEVI on HIV-1 and ZIKV infection of TZM-bl cells, an HeLa-
derived cell line permissive for HIV-157 and ZIKV (Fig. 1). ZIKV
infection rates were determined as described above, while HIV-1
infection rates were monitored by the expression of viral p24
capsid antigen instead of protein E from ZIKV. While HIV-1
infection was markedly increased by SEVI, ZIKV infection
was unaffected (Supplementary Fig. 2b). Thus, seminal amyloid
does not enhance the infectivity of ZIKV, in contrast to other
sexually transmitted viruses like HIV-138, herpes simplex virus-2
(HSV-2)58, and cytomegalovirus (CMV)59.
SE and seminal plasma inhibit ZIKV infection. Given the
importance of SE fibrils for the HIV-enhancing effect of
SE38–40,43, and our observation that these fibrils do not enhance
ZIKV infection (Supplementary Fig. 2), we anticipated that SE,
like SE fibrils, would not increase ZIKV infection. To analyze the
effects of SE on ZIKV infection, ejaculates from 20 individuals
were liquefied and then combined to generate pooled SE. The
pooled SE was then aliquoted and frozen at −80 °C or centrifuged
to obtain the cell-free supernatant, termed seminal plasma (SP),
which was also aliquoted and frozen at −80 °C. SE and SP were
titrated onto Vero E6 cells at concentrations up to 5%, and then
cells were infected with both ZIKV strains. To minimize cytotoxic
effects of SE and SP39,60,61, the inoculum was removed after 2 h,
and fresh medium without SE/SP was added. Infection rates were
determined 2 days later by quantifying ZIKV E protein in a cell-
based immunodetection assay. Surprisingly, SE and SP effectively
suppressed ZIKV infection (Fig. 3a). A final cell culture con-
centration of 1% SE or SP reduced ZIKV MR766 and GWUH
infection by >90%, and a concentration of 5% SE or SP almost
entirely abrogated infection (Fig. 3a), in the absence of any cyto-
toxicity (Supplementary Fig. 3). Effective inhibition of ZIKV
infection by SP and SE was confirmed by fluorescence microscopy
(Fig. 3b–d and Supplementary Fig. 4) and flow cytometry (Fig. 3e
and Supplementary Fig. 5). To exclude the possibility that SE or
SP may interfere with antibody-based detection of the viral anti-
gen, cells that were infected in the absence or presence of SE or SP
were also analyzed microscopically. At day 5 postinfection, ZIKV
MR766 and GWUH induced massive cytopathic effects (CPEs), as
indicated by rounded and detached cells (Supplementary Fig. 6).
In the presence of 1% SE or SP, no CPE was visible in ZIKV-
exposed cells, and cells were morphologically similar to uninfected
cells (Supplementary Fig. 6). These results are consistent with the
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Fig. 1 ZIKV infects and replicates in cells of the anogenital tract. a Primary HFFs and eSFs and cell lines derived from the cervix (HeLa), colon (SW480), or
ovaries (OVCAR-3 and SKOV3) were inoculated with ZIKV MR766. Two days later, cells were stained for flavivirus protein E (green), nuclear DNA (blue),
and actin (red) and imaged by confocal microscopy. Scale bars correspond to 20 µm. b Supernatants of infected cells of the anogenital tract were taken at
days 0, 1, 3, and 5, and viral genome copy numbers were determined by qPCR. c Infectious virus titer of supernatants was determined by TCID50 titration
onto Vero E6 cells. HFF: human foreskin fibroblast, eSF: endometrial stromal fibroblast
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inability of SE fibrils to enhance ZIKV infection and further show
that human SE potently inhibits ZIKV infection.
ZIKV suppression is a general property of human SE. As the
previous set of experiments used pooled SE/SP, it was possible
that a potent inhibitor of ZIKV infection was present in SE from
only a subset of individuals. To assess how common this inhibitor
is, we next determined the inhibitory activity of ten ejaculates
from different donors. All ten ejaculates efficiently inhibited
ZIKV GWUH (Fig. 4a) and MR766 (Supplementary Fig. 7a)
infection. The average half-maximal inhibitory concentration
(IC50 ± standard deviation of 3 replicates) was 0.74 ± 0.18% for
ZIKV GWUH, and 0.84 ± 0.11% for MR766 (Table 2). Again, 5%
SE almost completely blocked infection of both ZIKV strains.
Similar results were obtained with SE that was pooled from these
ten donors with IC50s against GWUH and MR766 of 0.67 and
0.76%, respectively (Fig. 4a, Supplementary Fig. 7a and Table 2).
Thus, the inhibitory activity of SE appears to be a general
property and is not donor specific.
SE inhibits ZIKV by blocking viral attachment to cells. Results
shown in Figs. 3 and 4a and Supplementary Fig. 7a were obtained
by exposing cells to 5, 1, 0.2, 0.04, and 0% SE, followed by
inoculation with ZIKV (“cell treatment”). To determine whether
the ZIKV inhibitory activity is directed against the cell or the viral
particle, the two ZIKV strains were first treated with 50, 10, 2, 0.4,
and 0% SE and then added to target cells (“virion treatment”).
This experimental set-up resulted in a ten-fold higher SE con-
centration during virion incubation but same final SE con-
centrations in cell culture as the “cell treatment” set-up. As shown
in Fig. 4b and Supplementary Fig. 7b, SE concentrations up to
50% during virus pretreatment efficiently inhibited ZIKV
Table 1 Replication of ZIKV in ex vivo-infected vaginal and endometrial tissues
ZIKV MR766 ZIKV GWUH
VT (n= 6) ET (n= 7) VT (n= 7) ET (n= 7)
Productive infectiona 4/6 7/7 6/7 4/7
Max. titer (TCID50/ml)b 8.89 × 105 (#6, day 4) 1.58 × 106 (#13, day 8) 2.32 × 106 (#1, day 8) 1.58 × 105 (#13, day 4)
VT vaginal tissue, ET endometrial tissue, # donor
a Number of tissues that were productively infected/number of all tissues analyzed; tissues were considered to be productively infected if infectious virus titers were ≥10-fold greater than the wash
control
b Highest ZIKV titer measured; the numbers in brackets indicate the donor and the day postinfection that the supernatant was taken
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Fig. 2 ZIKV infects and replicates in primary vaginal and endometrial tissue. a, b Primary vaginal tissue (VT) or c, d endometrial tissue (ET) blocks were
infected for 2 h with ZIKV MR766 (a, c, in red) or GWUH (b, d, in blue). Blocks were then washed in PBS, transferred onto foams, and cultured for up to
8 days. Aliquots of the supernatants were taken at day 0 (wash control) and days 4, 6, and 8 and then analyzed for infectious titer by TCID50 titration on
Vero E6 cells. Maximum fold-increase titers were compared to the wash control (day 0) and are indicated in italics above the corresponding bars. ¶No
samples collected on that day. See also Table 1
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infection. Of note, the IC50s were similar to those obtained for the
“cell treatment” set-up (Table 2). These observations demonstrate
that final SE concentrations in cell culture, rather than the con-
centrations acting on the virion, determine the efficiency of
inhibition, thereby suggesting that the inhibitory factor is acting
on the target cell and not the virion.
To clarify which step in the viral life cycle is blocked, “time of
addition” experiments were performed. When ZIKV and SP were
added simultaneously, infection was blocked, as expected (Fig. 4c,
ZIKV+SP). In contrast, when cells were first infected, followed by
a washing step and addition of SP 2 h later (after the virus has
already entered the cell), no antiviral effect was observed (Fig. 4c,
ZIKV→SP). These data suggest that SP inhibits an early event in
the viral life cycle. Alternatively, if cells were first treated with SP
and then washed to remove the inhibitor, limited inhibition was
observed (Fig. 4c, SP→ZIKV) demonstrating that the antiviral
activity of SP is reversible. To clarify whether SP may interfere
with ZIKV binding to the target cell, we established a confocal
microscopy-based assay that quantifies ZIKV attachment. For
this, a confluent layer of Vero E6 cells was inoculated with
increasing concentrations of ZIKV for 2 h at 37 °C or 4 °C,
then cells were fixed, washed, attached virions were stained, and a
z-stack of confocal microscopy images was taken. Cell-associated
ZIKV particles were readily detectable (Supplementary Figs. 8a,
9a) and quantifiable (Supplementary Figs. 8b, 9b) at a multiplicity
of infection (MOI) >1. Increasing concentrations of SP reduced
fluorescence intensities in a dose-dependent manner, with 5% SP
inhibiting ZIKV attachment almost completely (Fig. 4d, e and
Supplementary Figs. 8c, d and 9c, d). Together these data show
that SE prevents the initial binding of Zika virions to target cells.
SE-derived extracellular vesicle preparations inhibit ZIKV. To
investigate whether the factor(s) in SE that is responsible for the
anti-ZIKV activity is a peptide or protein, SP was subjected to
Proteinase K digestion (Supplementary Fig. 10a) or treatment
with heat (Supplementary Fig. 10b) or acid (Supplementary
Fig. 10c) to denature proteins. None of these treatments abolished
the antiviral activity of SP demonstrating that the antiviral factor
is not a polypeptide. Using lectin affinity chromatography
(Concanavalin A columns) to remove glycosylated macro-
molecules from SP, we found that glycoproteins are also not
involved in the anti-ZIKV activity (Supplementary Fig. 10d). We
then assessed the size of the responsible factor. SP that was syr-
inge filtered through 0.2 μm pores retained antiviral activity
(Fig. 5a). When SP was centrifuged through a 300 kDa filter, the
antiviral activity was found in the retentate, whereas the filtrate
was inactive (Fig. 5b). Thus the anti-ZIKV factor in cell-free SP
has a molecular weight above 300 kDa but passes through
200 nm-diameter pores. SE contains huge amounts of structurally
diverse, extracellular vesicles (EVs) with sizes between 50 and
400 nm62,63. To analyze the effect of large and small EVs on
ZIKV infection, SP was centrifuged through 0.65 μm filters, after
which the filtrate was transferred to 0.22-μm centrifugal filters, as
described64. Large EVs were recovered from the top of the filters
by washing, while small EVs were obtained as flow through64.
Both EV preparations inhibited ZIKV infection with EVs
<220 nm being as potent as non-processed SP (Fig. 5c). This
sample contained particles with an average diameter of 141.6 ±
3.7 nm (Supplementary Fig. 11a). Such particles were largely
absent in the 300 kDa filtrate that does not contain inhibitory
activity (Fig. 5b and Supplementary Fig. 11b). The SP-derived EV
0
20
40
60
80
100
120
MR766 GWUH
In
fe
ct
ed
 c
el
ls
 (
%
)
SP (%)
0 0.2 1 5
***
***
***
0
20
40
60
80
100
120
140
160
180
SE SP SE SP
MR766 GWUH
In
fe
ct
io
n 
(%
)
0 0.04 0.2 1 5
SE/SP (%)
***
*** ***
***
**
** ****
0
20
40
60
80
100
120
MR766 GWUH
In
fe
ct
ed
 c
el
ls
 (
%
)
SE (%)
0 0.2 1 5
***
***
***
***
U
ni
nf
ec
te
d
M
R
76
6
G
W
U
H
0.2% 1% 5%
+SP
+
Z
IK
V
ba
ec d
0
200
400
600
800
1000
1200
MR766 GWUH
M
F
I
0 0.2 1 5
***
**
****
*
SP (%)
Fig. 3 Semen and seminal plasma inhibit ZIKV infection. a Vero E6 cells were incubated with the indicated concentrations of SE or SP and inoculated with
ZIKV MR766 or GWUH. Two days later, infection rates were determined by a cell-based ZIKV immunodetection assay that enzymatically quantifies the
flavivirus protein E. Data are normalized to infection rates in absence of SE or SP and represent average values obtained from triplicate infections ± standard
deviations. b Vero E6 were incubated with the indicated concentrations of SP before inoculation with the two ZIKV strains. Two days postinfection, cells
were stained for flavivirus protein E (green) and nuclear DNA (blue) and visualized by fluorescence microscopy. Scale bar corresponds to 200 µm. c
Quantification of protein E-positive cells in b ±standard deviation of triplicate infections, conducted with ImageJ. d Quantification of ZIKV infection in
presence of SE based on microscopy data (see Supplementary Fig. 4). eMean fluorescence intensity (MFI) of ZIKV-infected Vero E6 cells assessed by flow
cytometry (see Supplementary Fig. 5). *P < 0.01, **P < 0.001, ***P < 0.0001 (by one-way ANOVA with Bonferroni post-test)
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preparation only marginally lost antiviral activity when boiled
(Fig. 5d). This is in agreement with only a small shift in the size
distribution (Supplementary Fig. 11c) of EVs and only marginal
effects on vesicle morphology (Supplementary Fig. 11d) upon
boiling. This result suggests that the functionality of this EV
preparation might not depend on protein or RNA constituents.
Confirming an effect on virion particle binding to target cells, EV
preparation inhibited ZIKV attachment with similar efficiency as
SP (Fig. 5e, f and Supplementary Fig. 12). In comparison, EV
preparations derived from urine and saliva that are of similar or
slightly larger sizes did not affect ZIKV infection (Supplementary
Fig. 13). In conclusion, the SP fraction containing abundant EVs
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Fig. 4 The anti-ZIKV activity in semen is donor independent and targets an early step in the viral life cycle. a Vero E6 cells were incubated for 10 min with
the indicated concentrations of SE derived from ten individual donors or a pool of all ten samples. Cells were then inoculated with ZIKV GWUH and
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and then added to Vero E6 cells resulting in similar final SE concentrations as shown in a. This experimental set-up differs from the “cell treatment”
protocol used in a in that ZIKV is first treated with high concentrations of SE. Infection rates were determined by a cell-based ZIKV immunodetection assay
2 days postinfection. Data are normalized to corresponding infection in absence of SE/SP and represent average values obtained from triplicate infections
± standard deviations. For IC50 values, see Table 2. c Vero E6 cells were inoculated with (i) SP and ZIKV simultaneously (ZIKV+SP); (ii) first ZIKV and
then, after a washing step, SP 2 h later (ZIKV→SP), or (iii) first SP and then, after a washing step, ZIKV 2 h later (SP→ZIKV). After another 2 h, medium
was changed and 2 days later infection rates measured. d ZIKV virions were allowed to attach to Vero E6 cells in the presence of the indicated
concentrations of SP for 2 h at 37 °C or e at 4 °C. Cells were then washed and stained for ZIKV protein E and cell nuclei. A z-stack of 14 confocal
microscopic images were taken and combined to a maximum intensity projection. Protein E fluorescence was quantified and normalized to the absence of
SP in three z-stacks ± standard deviation (see Supplementary Figs. 8c, d and 9c, d). *P < 0.01, **P < 0.001, ***P < 0.0001 (by one-way ANOVA with
Bonferroni post-test)
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Fig. 5 Seminal extracellular vesicles inhibit ZIKV infection. a 50% SP was filtered through a 0.2 µm syringe filter. b 0.2 µm filtered SP was applied to a
300 kDa molecular weight filter and the retentate and filtrate diluted with PBS to the originally applied volume. c SP was separated into extracellular
vesicles (EVs) larger and smaller than 220 nm by centrifugal size filtration. d EV samples generated in c were boiled at 99 °C for 20min, centrifuged, and
denatured protein discarded. All samples (a–d) were added to Vero E6 cells at the indicated concentrations and incubated for 10min before cells were
inoculated with ZIKV MR766. After 2 days, infection was determined by cell-based ZIKV immunodetection assay that enzymatically quantifies the
flavivirus protein E. Average infection rates are normalized to the corresponding infection averages in the absence of SP. Data represent average values
obtained from triplicate infections ± standard deviations. e ZIKV virions were allowed to attach to Vero E6 cells in the presence of the indicated
concentrations of SP-derived EVs (<220 nm) for 2 h at 37 °C or f 4 °C. Cells were then washed and stained for ZIKV protein E and cell nuclei. A z-stack of
14 confocal microscopic images were taken and combined to a maximum intensity projection. Protein E fluorescence was quantified and normalized to the
absence of EVs in three z-stacks ± standard deviation (see Supplementary Fig. 12). *P < 0.01, **P < 0.001, ***P < 0.0001 (by one-way ANOVA with
Bonferroni post-test)
Table 2 Anti-ZIKV activity of individual (n= 10) SE samples and pooled SE
IC50 [% ±SD] average IC50 [%] pooled SE IC50 [%] Min. IC50 [%] Max.
ZIKV GWUH Cell treat. 0.74 ± 0.18 0.67 0.49 0.98
Virion treat. 1.02 ± 0.33 0.71 0.65 1.84
ZIKV MR766 Cell treat. 0.84 ± 0.11 0.76 0.71 1.11
Virion treat. 1.00 ± 0.25 0.92 0.68 1.39
Shown are IC50 values derived from experiments shown in Fig. 4a, b and Supplementary Fig. 7a, b. Average IC50 values represent means derived from the 10 donors; Min., lowest IC50 measured; Max.,
highest IC50 measured
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is responsible for the observed anti-ZIKV activity of SE. However,
the exact nature of the antivirally active constituent in the EV
preparations from SE remains to be determined.
A fresh ejaculate inhibits ZIKV. The results presented thus far
were generated using freeze/thawed SE or SP. To exclude that the
freeze/thaw process is responsible for the observed anti-ZIKV
activity, we tested a freshly derived liquefied ejaculate (SE) and SP
derived from this fresh sample. Fresh SE and SP both efficiently
blocked ZIKV MR766 and GWUH infection of Vero E6 cells
under both “cell treatment” (Supplementary Fig. 14a) and “virion
treatment” (Supplementary Fig. 14b) conditions. Again, 1% SE or
SP reduced ZIKV infection by >90%, and infection was almost
entirely prevented by 5% SE or SP, corroborating results obtained
with frozen samples.
SE inhibits Dengue and West Nile virus infection. We next
tested whether SE may also inhibit infection by Dengue virus
(DENV), another mosquito-transmitted flavivirus. For this, Vero
E6 cells were infected with ZIKV or DENV in the presence of SE
or SP, and after 2 days, intracellular E protein expression levels
were measured by the in-cell immunodetection assay. SE and SP
both inhibited ZIKV (Fig. 6a) and DENV (Fig. 6b) infections with
similar efficiencies. These results were confirmed in Huh-7 cells
using a DENV reporter virus expressing Renilla luciferase (Sup-
plementary Fig. 15a, b). We further demonstrated that, similar to
ZIKV (Fig. 2), DENV infection was not affected by SEVI fibrils
(Supplementary Fig. 15c, d). Finally, we demonstrated that SE
also effectively inhibited infection by West Nile virus (WNV)
(Fig. 6c). Thus, SE suppressed infection by ZIKV, DENV, and
WNV.
SE enhances HIV-1 while inhibiting ZIKV infection. In con-
trast to ZIKV, DENV, and WNV, HIV-1 infection is enhanced by
SE or SP38–40. To make sure differences in the performance or
variation in SE batches did not account for the seemingly
opposite effects of SE on HIV-1 and flavivirus infection, we next
tested the effect of SE on ZIKV and HIV-1 simultaneously under
the same experimental set-up and conditions. An MOI of ~0.05
of ZIKV or HIV-1 was incubated with 50% SE or serial five-fold
dilutions thereof. The SE-treated virions were added to TZM-bl
cells, which are permissive for both HIV-1 and ZIKV (Supple-
mentary Fig. 2b). After 2 h, the inoculum was removed and fresh
medium was added. HIV-1 infection rates were determined
quantifying cell-associated β-galactosidase57,61 and ZIKV infec-
tion by the in-cell immunodetection assay. As expected38, SE
markedly increased HIV-1 infection with a maximum enhance-
ment of 23-fold when virions were pre-exposed to 10% SE
(Fig. 6d, e). In contrast, ZIKV infection was efficiently suppressed
when the same experimental set-up was applied and almost
entirely blocked by 50% SE (Fig. 6d, e). Thus, the identical SE
batch and treatment conditions enhance infection by HIV-1 while
inhibiting infection by ZIKV.
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Fig. 6 Semen and seminal plasma inhibit Dengue and West Nile virus but enhance HIV-1 infection. Vero E6 cells were incubated with the indicated
concentrations of SE or SP and inoculated with a ZIKV MR766 or b DENV-2 (Thailand/16681/84). Two days later, infection rates were determined by a
cell-based ZIKV and DENV immunodetection assay that enzymatically quantifies the flavivirus protein E. c WNV NY99 was used to infect Huh-7 cells in
the presence of the indicated concentrations of SE. Twenty four hours later, supernatants were collected and used to detect viral titers in a plaque assay. d
Similar MOIs of ZIKV GWUH and HIV-1 NL4-3 92TH014.12 were incubated with 0, 0.4, 2, 10, or 50% of SE for 10min. Vero E6 or TZM-bl cells were then
inoculated with the SE-treated virions. Two days later, infection rates were determined by a cell-based ZIKV immunodetection assay or by quantifying
β-galactosidase activity of cell lysates for HIV-1. Data are plotted on a linear y axis. e Data from d are plotted on a logarithmic y axis to better visualize
inhibition of ZIKV infection. Numbers above the columns indicate fold enhancement of infection levels. Data are normalized to infection rates in the
absence of SE or SP and represent average values obtained from triplicate (WNV: duplicate) infections ± standard deviations. *P < 0.01, **P < 0.001, ***P <
0.0001 (by one-way ANOVA with Bonferroni post-test)
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SE inhibits infection of anogenital cells and tissues. We then
tested whether SP is capable of inhibiting ZIKV infection of cells
of the anogenital tract. We used SP instead of SE so that endo-
genous cells would not hamper the visualization of infected cells
by confocal microscopy. We observed that SP concentrations of
1% markedly reduced infection of primary HFF and the HeLa,
SW480, and SKOV3 cell lines (Fig. 7a, b). A final SP con-
centration of 5% completely inhibited ZIKV infection of primary
eSFs, and a SP concentration of 25% completely inhibited infec-
tion in all analyzed cells (Fig. 7a, b). Cellular morphology as well
as staining of the cytoskeleton and nuclei were similar for unin-
fected and SP-exposed cells, excluding the possibility that cyto-
toxic effects of SP contributed to reduced ZIKV infection rates.
Finally, we determined whether SE can block ZIKV replication
in vaginal explants. Explants from two donors were cut into 48 or
96 tissue blocks, respectively, divided into two equal parts in
15 ml tubes, and exposed to ZIKV in the absence or presence of
SE (25%). After 90 min, blocks were thoroughly washed and each
block was cultured individually in 96-well plates. Viral loads were
determined immediately (wash control) and after 4 (tissue 1) or
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Fig. 7 Seminal plasma inhibits ZIKV infection of cells of the anogenital tract. a Primary HFFs and eSFs and cell lines derived from the cervix (HeLa), colon
(SW480), or ovaries (OVCAR-3 and SKOV3) were incubated with the indicated concentrations of SP and inoculated with ZIKV MR766. Two days later,
cells were stained for protein E (green), nuclear DNA (blue), and actin (red) and then imaged by confocal microscopy. Scale bars correspond to 20 µm.
b Fluorescence signal intensity was quantified and normalized to infection in absence of SP from three images ± standard deviation. HFF: human foreskin
fibroblast, eSF: endometrial stromal fibroblast, *P < 0.01, **P < 0.001, ***P < 0.0001 (by one-way ANOVA with Bonferroni post-test)
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5 days (tissue 2). Consistent with Supplementary Fig. 1, ZIKV
replicated in the majority of the individual tissue blocks (Fig. 8a,
b). Importantly, in the presence of 25% SE, viral loads were
reduced on average by 79% (P= 0.0198, two-way repeated-
measures (RM) analysis of variance (ANOVA)) (Fig. 8a) and
73.4% (P= 0.0326, two-way RM ANOVA) (Fig. 8b), respectively.
Compared to infection experiments in cell lines and primary cells
where 25% SE suppressed ZIKV entirely (Fig. 7), the antiviral
efficacy of SE in tissues was slightly reduced, which is likely due to
the higher virus inoculum required to achieve reliable infection
and viral spread over the course of 4–5 days. A cytotoxicity assay
performed with tissue blocks of donor A at day 8 revealed no
signs of reduced viability in the presence of SE (Fig. 8c). Thus, SE
suppresses productive ZIKV replication in primary VTs.
Discussion
In this study, we used in vitro and ex vivo systems to characterize
sexual transmission of ZIKV. It has been calculated that, upon
male-to-female sexual contact, up to ~108 infectious ZIKV parti-
cles from a viremic individual (present in an average ejaculate
volume of ~3.7 ml) may be deposited into the FRT65. Considering
the high viral titers in SE and our demonstration that cell lines,
primary cells, and tissues derived from the anogenital region
efficiently support productive ZIKV infection, it is surprising that
the rates of sexual ZIKV transmission are low compared to
mosquito-mediated transmission, where typically only 102 infec-
tious virions are injected intravascularly65,66. Our results reported
here suggest that the reason why ZIKV has not turned into a
sexually transmitted epidemic may be explained by the fact that SE
is a powerful inhibitor of ZIKV infection. SE prevented ZIKV
infection of cells derived from the anogenital tract including VT,
suggesting that this intrinsic anti-ZIKV activity of SE may also
prevent male-to-female genital ZIKV transmission in vivo.
ZIKV has previously been reported to infect skin fibroblasts,
keratinocytes, dendritic cells55, placental cells, and neuronal
progenitors67. We here confirm that ZIKV also replicates in
isolated eSFs68 and show that the tropism extends to cervix-,
colon- and foreskin-derived cells (Fig. 1) and most notably to
explant tissues derived from endometrium and vagina (Fig. 2 and
Supplementary Fig. 1). These explants largely resemble the cyto-
architecture present in vivo and allow for the ex vivo study of
viral replication in three-dimensional cultures. Our findings fur-
ther underline the notion that ZIKV has a broad cellular tropism
and that permissive cells are located at potential entry sites of
sexual transmission.
Inhibition of ZIKV infection was observed with pooled SE
derived from multiple donors (Figs. 3, 6, 8 and Supplementary
Figs. 4, 6), with SE from individuals (Fig. 4 and Supplementary
Fig. 7), and with a fresh ejaculate (Supplementary Fig. 14), sug-
gesting that viral inhibition is a general property of this bodily
fluid. The anti-ZIKV effect is mediated by a soluble factor because
SP, the cell-free supernatant of SE, also markedly suppressed
infection (Figs. 3, 4, 5, 6, 7, and Supplementary Figs. 5, 6, 10). The
factor reversibly inhibits an early step in the viral life cycle, since
adding SE after infection has been initiated does not limit viral
replication (Fig. 4c). This antiviral activity is directed toward the
cell since the final cell culture concentration (and not con-
centrations during virion treatment) determined the magnitude
of the anti-ZIKV effect of SE (Fig. 4, and Supplementary Figs. 7,
14). Consistent with these observations is our finding that SP
abrogates the attachment of virions to target cells (Fig. 4d, e and
Supplementary Fig. 8c, d and 9c, d).
The exact nature of the constituent in SE responsible for ZIKV
inhibition remains to be determined. Our results show that this
factor is present in EV preparations (Fig. 5c, d). We found that a
SE fraction containing EVs ~<220 nm in diameter inhibit ZIKV
infection as efficiently as SP (Fig. 5c), whereas EV preparations
from urine and saliva had no effect (Supplementary Fig. 13).
Moreover, the SP-derived preparation also prevented ZIKV
attachment (Fig. 5e, f and Supplementary Fig. 12), as observed for
SP (Fig. 4d, e and Supplementary Figs. 8c, d and 9c, d), and
contained EVs with an average diameter of ~142 nm (Supple-
mentary Fig. 11a) that are largely thermoresistant (Supplementary
Fig. 11b, c). In contrast, a SP fraction devoid of EVs did not
abrogate ZIKV infection (Fig. 5b and Supplementary Fig. 11b).
EVs are small vesicles released by cells and are common com-
ponents of many bodily fluids69. Human SE contains an extra-
ordinary high concentration of EVs with an average number of ~
1 × 1013 vesicles per ml SE70. A recent cryo-electron microscopic
analysis of human SE revealed 11 subcategories of EVs, including
multifaceted assemblies, with diameters between ~20 and
400 nm69. The great morphological diversity accompanies the
functional diversity of seminal EVs, which are involved in sperm
motility, SE liquefaction, immunosuppression in the female genital
tract to avoid anti-spermatozoa immunity, and prevention of
microbial infections69. Which particular type or constituent in the
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Fig. 8 Semen reduces ZIKV infection of primary vaginal tissue. a 2 × 24 vaginal tissue blocks of donor A, and b 2 × 48 blocks of donor B were incubated for
90min with ZIKV GWUH in the presence of 25% semen or 25% PBS. After washing, individual blocks were transferred into separate wells of a 96-well
plate and incubated at 37 °C. Aliquots were taken at day 0 (wash control) or day 4 or 5 and examined for viral genome copy numbers by qPCR. *P < 0.05,
**P < 0.01, ***P < 0.001 (by two-way RM ANOVA with Tukey’s multiple comparison post-test). c 3 × 16 vaginal blocks were treated with PBS, 25% semen,
or 0.05% triton for 90min. After washing, blocks were incubated in separate 96 wells for 8 days and viability was examined by CellTiter-Glo® luminescent
cell viability assay. Black lines indicate averages ± standard error of the mean, RLU/s relative light units per second. ns: not significant, *P < 0.05 (by one-
way ANOVA with Bonferroni post-test)
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EV preparations exerts anti-ZIKV activity and the precise
mechanisms employed needs to be clarified in subsequent studies.
One plausible explanation is, however, that the cellular target of
the functional entity is a ubiquitously expressed receptor or
attachment factor, which is utilized by ZIKV for infection.
Moreover, this cellular structure is conserved between African
green monkeys and humans, as SE blocks infection of cells derived
from both species (Figs. 3, 7). The identification of this conserved
cellular target will not only explain how SE might prevent ZIKV
infection but may also identify a novel attachment factor, which is
necessary for not only ZIKV but also DENV and WNV entry.
Our finding that SE and SP inhibit ZIKV infection came as a
surprise. We and others have previously shown that SE enhances
HIV-138, HSV-258, and CMV59 infection. This infectivity-
promoting effect was attributed to positively charged amyloid
fibrils in SE which concentrate the virions that are encased by a
negatively charged membrane. This in turn increases viral
attachment to and fusion with cellular targets43. However, syn-
thetic SEVI fibrils neither enhanced nor inhibited ZIKV infection,
suggesting that seminal amyloid does not interact with the ZIKV
particle. This could be explained by the fact that the Zika virion is
covered by a dense coat of the viral E protein, which renders the
viral lipid membrane largely inaccessible to large external fac-
tors71, such as seminal fibrils. In contrast, the membrane of HIV-
1 is largely accessible, because only a few viral glycoproteins are
embedded72, allowing efficient interaction of fibrils with HIV-1
particles. Further studies with viruses containing well-defined
numbers of viral glycoproteins are needed to clarify whether the
accessibility of the viral membrane determines fibril-mediated
enhancement of viral infection. In addition, the effect of seminal
amyloids on other emerging and re-emerging viruses should be
determined to assess its potential to be transmitted via sexual
intercourse.
With the realization that SE is not simply a passive carrier of
ZIKV, but rather significantly inhibits infection rates in vitro,
animal studies are urgently needed to determine the antiviral
efficacy of SE on vaginal or rectal ZIKV infection, in order to
better predict whether SE is likely to play a role in preventing
sexual ZIKV transmission in humans. Another intriguing ques-
tion is whether ZIKV is capable of acquiring resistance against the
inhibitory factor(s) in SE that may increase the frequency of
sexual transmission to a level allowing spread of this human
pathogen in areas where no mosquitoes are present. Finally, it
would be of interest to evaluate whether SE may exert similar
effects on other flavi- or arthropod-borne viruses. Our results
presented here show that SE also restricts DENV and WNV
infection. Sexual transmission of hepatitis C virus is an extremely
infrequent event73 and has never been recorded for Dengue, West
Nile, yellow fever, or Chikungunya virus, although these viruses
may be shed into SE of infected individuals74–76. Clarifying
whether SE has a broad-based anti-flavivirus activity may help
explain why certain pathogens are typically not, or only very
infrequently, transmitted via sexual intercourse.
Methods
Cell and tissue culture. Vero E6 (Cercopithecus aethiops-derived epithelial kidney)
(ATCC, CRL-1586) cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 2.5% inactivated fetal calf serum (FCS), 2 mM L-
glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyr-
uvate, and non-essential amino acids (Sigma #M7145). HeLa (human epithelial
cervix carcinoma) (ATCC, CCL-2), TZM-bl (HeLa-based HIV-1 reporter)
(ARRRP, 8129), and SKOV3 (human epithelial ovary carcinoma) cells (ATCC,
HTB-77) were grown in DMEM supplemented with 10% FCS, 2 mM L-glutamine,
100 units/ml penicillin, and 100 μg/ml streptomycin. Huh-7 (differentiated
hepatocyte-derived carcinoma) cells (authenticated by SNP profiling at Multi-
plexion) were grown in DMEM supplemented with 10% FCS, 100 units/ml peni-
cillin, 100 μg/ml streptomycin, and non-essential amino acids. SW480 (human
epithelial colon carcinoma) (ATCC, CCL-228) and OVCAR-3 (human epithelial
ovary carcinoma) cells (ATCC, HTB-161) were grown in RPMI-1640 supple-
mented with 10% FCS, 2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml
streptomycin. HFFs were isolated from tissue samples that were residuals from
routine procedures and obtained anonymized after written informed consent of the
parents in agreement with articles 21 and 23 of the recommendations of the council
of Europe (2006). HFFs were grown in minimal essential medium (MEM) sup-
plemented with, 2 mM L-glutamine, 10% FCS and non-essential amino acids,
100 units/ml penicillin, and 100 μg/ml streptomycin. T84 (human epithelial colon
carcinoma) cells (ATCC, CRL-248) were grown in a 1:1 mixture of Ham’s F12
medium and DMEM supplemented with 2 mM L-glutamine, 5% FCS, 100 units/ml
penicillin, and 100 μg/ml streptomycin. Primary human eSFs were obtained from
the Cooperative Human Tissue Network (CHTN) (IRB # 14-15361) and isolated
and cultured as described (http://www.bio-protocol.org/e1623)77 in SCM medium
consisting of 67.5% DMEM with 1 mM sodium pyruvate, 22.5% MCDB-105, 5 μg/
ml insulin, 10% FCS, 100 units/ml penicillin, and 100 μg/ml streptomycin. C6/36
(Aedes albopictus) mosquito cells (ECACC, 89051705) were grown in Leibovitz L-
15 medium (Gibco) supplemented with 10% FCS, 100 units/ml penicillin, 100 μg/
ml streptomycin, and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.
Blocks cut from surgically removed tissue of cervix and vagina of pelvic organ
prolapse patients who gave informed consent (approved by the ethics committee of
Ulm University) were cultured in extracellular medium (ECM) consisting of RPMI
with 15% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, non-essential amino
acids, 100 units/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml gentamicin, and
25 μg/ml Amphotericin B. All experiments in the presence of SE and SP were
performed in the presence of 100 μg/ml gentamicin to prevent bacterial outgrowth.
Mosquito cells were cultured at 28 °C and human and monkey cells and tissues
were cultured at 37 °C in a 5% CO2 humidified incubator. All cell lines were
regularly tested for mycoplasma contamination.
SE and SP. SE from healthy donors was obtained from the “Kinderwunsch-
Zentrum Ulm”, a fertility center in Ulm, or healthy volunteers at Ulm University,
after informed consent had been given (approved by the ethics committee of
Ulm University). Ejaculates were allowed to liquefy for 30 min and then stored
at −80 °C as individual or pooled samples. SP was generated by centrifugation of
SE for 30 min at 20,000 × g at 4 °C and collection of the cell-free supernatant.
Viruses. Plasmid pBRNL4-3 92TH014.12 encodes the HIV-1 NL4 3 provirus in
which the V3-loop region was replaced by the V3-loop of the CCR5-tropic
92th014.12 isolate39,41,43,61. ZIKV strain MR766 was isolated in 1947 from a
sentinel rhesus macaque1. FB-GWUH-2016 is a ZIKV strain that was isolated in
2016 from a fetal brain with severe abnormalities54. DENV-2 (Thailand/16681/84)
cDNA was constructed from a serum-derived virus78. This virus was used to
construct the renilla luciferase encoding DENV-R2a79. WNV NY99 (385-99) was
isolated from the liver of a snowy owl (Nyctea scadiaca)80.
Virus stock generation and propagation. ZIKV was propagated by inoculation of
70% confluent Vero E6 cells in 175 cm² cell culture flasks for 2 h in 5 ml medium.
Subsequently, 35 ml fresh medium was added and the cells were cultured for
3–5 days. CPE was monitored by light microscopy and virus was harvested when
70% of the cells detached owing to CPE. Supernatants were centrifuged for 3 min at
325 × g to remove cellular debris and then aliquoted and stored at −80 °C as virus
stocks. TCID50 of each stock was determined by infection of Vero E6 cells with
serially diluted virus stocks and calculated according to Reed and Muench. The
genome copy number of the stocks was assessed by quantitative reverse
transcriptase-polymerase chain reaction (RT-qPCR; RealStar® Zika Virus RT-PCR
Kit, Altona Diagnostics, Hamburg, Germany) (see Supplementary Table 1).
DENV-R2a was propagated in Vero E6 cells. DENV-2 (Thailand/16681/84) and
WNV NY99 (and additionally for one experiment ZIKV MR766) were prepared by
virus amplification in insect C6/36 cells.
HIV-1 stocks were generated by transient transfection of HEK293T cells using
the calcium phosphate precipitation technique. HEK293T cells were seeded in 6-
well plates or 175 cm2 flasks, and the following day, when cells were at a confluence
of 60–80%, cells were replaced with fresh medium. A total of 5 μg (for 2 ml
medium per 6 well) or 125 μg (for 50 ml medium per 175 cm2 flask) of proviral
plasmid DNA was diluted in 125 mM CaCl2 and added dropwise to an equal
volume of 2× HBS. After 10 s of vortexing, the DNA precipitate was added
dropwise to the culture medium. Sixteen hours post-transfection, medium was
replaced with fresh DMEM (supplemented with 2.5% FCS) and incubated for
another 24 h. The supernatant, containing infectious virions, was centrifuged
(3 min, 325 × g) to remove cellular debris and transferred into reaction tubes. Virus
stocks were stored at 4 °C or frozen at −80 °C.
TCID50 end point titration of ZIKV. To determine infectious ZIKV titer, 6000
Vero E6 cells were seeded per well in 96 flat-bottom well plates in 100 μl medium
and incubated overnight. The next day, 80 μl fresh medium was added. For end
point TCID50 determination, ZIKV samples were titrated 10-fold, and 20 μl of each
dilution was used for inoculation of Vero E6 cells. This end point titration resulted
in final ZIKV dilutions of 10–109× on the cells in triplicates or sextuplicates. Cells
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were then incubated and monitored by microscopy for CPE and plaque formation.
TCID50/ml was calculated according to Reed and Muench.
CellTiter-Glo® luminescent cell viability assay. CellTiter-Glo® luminescent cell
viability assay (Promega #G7571) was performed according to the manufacturer’s
instructions. Briefly, medium was removed from the cells or tissue blocks, and 50 μl
phosphate-buffered saline (PBS) and 50 μl of reagent were added. After a 10 min
incubation, luminescence was measured in an Orion II Microplate Luminometer
(Titertek Berthold). Untreated controls were set to 100% viability. Error bars are
standard deviations of triplicates.
Fluorescence microscopy of ZIKV infection. Target cells were seeded in eight-
well μ-Slides (Ibidi) and incubated overnight. Cells were inoculated with 103–104
TCID50/ml of ZIKV. After 2 h, the inoculum was removed and cells washed with
PBS before fresh medium was added. After 2 days of culture, cells were washed
with PBS, fixed with 4% paraformaldehyde in PBS for 10 min at 4 °C, permeabi-
lized with 0.1% (v/v) Triton X-100 in PBS for 5 min, and washed again. Unspecific
binding sites were blocked by 30 min incubation with 5% (v/v) FCS and 1% (v/v)
bovine serum albumin (BSA) in PBS. Cells were stained with 1:10,000 diluted
mouse anti-flavivirus group antigen/protein E antibody (4G2) (absolute antibody,
Ab00230-2.0) in PBS with 1% (v/v) BSA for 45 min. After 3 washes with PBS, cells
were incubated with 1:1000 diluted goat anti-mouse secondary antibody con-
jugated to Alexa Fluor 488 (ThermoFisher Scientific, A11001) for 45 min and
stained with 0.3 μg/ml 4′,6-diamidino-2-phenylindole dihydrochloride (Sigma,
D9542). Alternatively, the nuclei were stained with 1:2000 diluted Hoechst 33342
(ThermoFisher Scientific, H1399) together with staining of actin filaments by 1:400
diluted Phalloidin-Atto 647 N (ATTO-TEC, AD 647N-82). Slides were imaged by
using an inverted fluorescence microscope. Images were generated from 3 × 3
individual images taken with a 20× objective lens of an Axio-Observer.Z1 fluor-
escence microscope, the Axiovision 4.8 software and the Mosaic software module
(Zeiss). Infected cells were counted using ImageJ with the ITCN (Image-based Tool
for Counting Nuclei) plugin. Phalloidin-stained samples were imaged by confocal
microscopy using a Zeiss LSM 710 and images processed using the ZEN software
2010, and infection intensity was quantified by measuring the total signal intensity
per image and subtracting the uninfected background using the ZEN software
2010.
ZIKV infection of VT and ET blocks. VT and ET preparation and infection was
performed similar to HIV-1 cervical tissue explant studies52,53. Tissues were cut
into 2 × 2 × 1mm3 tissue blocks. Six blocks were inoculated with ZIKV MR766 or
GWUH by incubation of the blocks individually in a 96-well containing 200 μl
medium and virus stock at 37 °C. After 2 h, blocks were washed 3 times with PBS,
and the 6 blocks together were transferred onto gelfoams that were prepared in a
12-well plate containing 800 μl ECM culture medium. Alternatively, to detect viral
replication in each single vaginal block, blocks were incubated with ZIKV in a
15 ml falcon, washed with PBS, and transferred into separate 96 wells containing
200 μl ECM culture medium. In all, 100 μl supernatant was collected immediately
(wash control, day 0) or at consecutive days, stored at −80 °C, and analyzed by
TCID50 titration for infectious virus titer or by RT-qPCR for viral RNA copy
numbers (see Supplementary Table 1).
Cell-based virus immunodetection assay. For infection, 6000 target cells were
seeded per 96-well flat-bottom well in 100 μl appropriate medium and cultured
overnight. After adding 80 μl of medium, cells were inoculated with 103–105
TCID50/ml ZIKV in triplicates. In experiments with SE or SP, medium was sup-
plemented with 100 μg/ml gentamicin to prevent bacterial outgrowth and changed
2 h after infection to minimize cytotoxic SE effects39,60,61. For cell treatment, cells
were incubated with 0, 0.04, 0.2, 1, and 5% SE and SP before inoculation with
ZIKV. For virion treatment, virus particles were preincubated with ten-fold higher
concentrations (0, 0.4, 2, 10, or 50%) of SE and SP before the mix was inoculated
(and diluted ten-fold) on cells. Two days post inoculation, infection rates were
determined by immunodetection of ZIKV-infected cells as already described56.
Cells were rinsed with PBS, fixed for 20 min with 4% paraformaldehyde, per-
meabilized with cold methanol for 5 min at 4 °C, and washed with PBS. Next, they
were incubated with 1:10,000 mouse anti-flavivirus group antigen/protein E anti-
body (4G2) (absolute antibody, Ab00230-2.0) or 1:1000 diluted anti-HIV-1 p24
antigen (mAK183) (EXBIO Antibodies) in PBS containing 10% (v/v) FCS and 0.3%
(v/v) Tween 20 for 1 h at 37 °C. Following 3 washes, cells were incubated with a
1:20,000 diluted horseradish peroxidase-coupled anti-mouse antibody (Thermo-
Fisher Scientific, A16066) for 1 h at 37 °C. Cells were then washed four times and
tetramethylbenzidine peroxidase substrate was added. After incubation at room
temperature for 5 min, the reaction was stopped with 0.5 M sulfuric acid.
Absorption was measured at 450 nm and the baseline was corrected at 650 nm
using a VMax Kinetic ELISA microplate reader. Values were corrected for the
background signal derived from uninfected cells, and triplicates were expressed as
average infection rates ± standard deviation.
Flow cytometry of ZIKV-infected cells. Six thousand Vero E6 cells were seeded
per 96 well and cultured overnight. The next day, cells were inoculated with SE
samples and ZIKV. After 2 h, the inoculum was removed, cells were washed with
PBS, and fresh medium was added. Two days later, cells were prepared for flow
cytometric analysis to determine cell death and infection rates. Cells were detached
from the well using 0.05% Trypsin/EDTA and resuspended in culture medium.
Cells were then transferred to V-bottom 96-well plates, washed with PBS, and
stained with fixable viability stain 450 for 15 min at room temperature. After a
washing step, the cells were fixed and permeabilized with buffer A (fix & perm,
Biozol, GAS002) for 15 min. Cells were then incubated with mouse anti-flavivirus
group antigen/protein E antibody (4G2) (absolute antibody, Ab00230-2.0) diluted
1:10,000 in buffer B (fix & perm, Biozol GAS002) for 30 min at 4 °C. After a
washing step, cells were incubated with 1:150 diluted goat anti-mouse secondary
antibodies conjugated with Alexa Fluor 488 (ThermoFisher Scientific, A11001) in
buffer B for 30 min protected from light. After further washing steps, cells were
resuspended in fluorescence-activated cell sorting buffer and measured in a BD
FACSCanto™ II Cell Analyzer. Unstained cells, single stained, and isotype controls
served as a control.
ZIKV virion attachment assay. Target cells were seeded in eight-well μ-Slides
(Ibidi, 80826) and incubated overnight. Cells were inoculated with ZIKV MR766
and incubated for 2 h at 37 °C or 4 °C. Subsequently, the inoculum was removed
and cells washed with PBS. To detect virion attachment, cells were prepared
immediately by immunofluorescence staining as described above. Attached virus
particles were imaged as z-stacks of 14 images by confocal microscopy using a Zeiss
LSM 710. Images were processed and combined to maximum intensity projections
using the ZEN software 2010. Attached virions were quantified by measuring the
total signal intensity per projection and subtracting the uninfected background
using the ZEN software 2010.
HIV-1 infection assay. HIV-1 infection was detected by cell-based immunode-
tection assay (see above) or by the reporter activity of TZM-bl cells. This human
cell line expressing CD4, CCR5, and CXCR4 encodes the lacZ gene under control
of the HIV-1 LTR promoter57. Upon infection by HIV and simian immunodefi-
ciency virus, the viral protein Tat induces β-galactosidase expression, allowing
quantification of infection by conversion of a chemiluminescent substrate. To
quantify HIV infection, 1 day prior to infection, 10,000 cells were seeded per well in
96-well flat-bottom microtiter plates in 100 μl medium. The next day, 80 μl med-
ium was added and cells were inoculated with 20 μl sample in triplicates. Media was
changed 2 h after inoculation to minimize cytotoxic SE effects (see http://www.bio-
protocol.org/e1871)61. Three days postinfection, medium was discarded and 40 μl
of diluted Gal-Screen® substrate/buffer A (1:8 in PBS) (ThermoFisher Scientific,
T1027) was added. During the 30 min room temperature incubation, cells were
lysed and the substrate converted by the released β-galactosidase. After incubation,
35 μl were transferred into white 96-well plates and substrate conversion was
measured as relative light units per second using the Orion II Microplate
Luminometer. Values were corrected for the background signal derived from
uninfected cells, and triplicates were expressed as average infection rates ± standard
deviation.
Plaque assay of WNV. VeroE6 were infected with serially diluted virus pre-
paration in DMEM at 37 °C. Inoculum was removed 2 h after infection and cells
were cultured in medium containing 1.5% carboxymethylcellulose. Cells were fixed
3 days postinfection by adding formaldehyde directly to the medium (5% final
concentration). Cells were washed with water and stained with 1% crystal violet/
10% ethanol for 30 min. Staining solution was removed and stained cells were
rinsed again with water. Plaques were counted and titers of infectious virus were
calculated.
SP treatments. Denaturation: SP was diluted 1:1 (v/v) in PBS and incubated
at 99 °C for 20 min in an Eppendorf Thermomixer. Samples were then centrifuged
for 15 min at 20,000 × g. The pellets were then discarded and the supernatants used
for further analyses.
Proteinase K digestion: SP was diluted 1:1 (v/v) in PBS containing 200 μg/ml
gentamicin and was incubated with 300 μg/ml Proteinase K (Roche, 03115887001)
for 5 h at 37 °C. To stop proteinase K activity, the sample was denatured and
centrifuged as described above.
Protein precipitation with 2,2,2,-tricholoroacetic acid (TCA): 0.2 μm syringe
filtered SP (described below) was incubated with 10% TCA at room temperature
for 1 h. Precipitated proteins were pelleted as described above and the supernatant
adjusted to pH 7–8 with NaOH.
Lectin affinity chromatography: SP was applied to HiTrap™ Con A 4B (GE
Healthcare, 28-9520-85) columns as described by the manufacturer. Briefly, the
columns were washed and equilibrated with binding buffer at a flow rate of 0.2 and
1 ml/min. Next, SP was diluted 1:10 (v/v) in binding buffer and filtered through 0.2
μm syringe filters before it was applied to the columns at a flow rate of 0.1–0.5 ml/
min. The filtrate was collected and the retentate eluted using 0.1 M and 0.5 M
methyl-αD-glucopyranoside elution buffer. Buffers were exchanged by 3K Amicon
centrifugal filters (see below) to PBS at the original volume of SP.
Size filtration: SP was diluted 1:1 (v/v) in PBS before it was applied to 0.2 μm
syringe filters and the filtrate was used for further experiments.
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Molecular weight filtration: SP was diluted 1:1 (v/v) in PBS and centrifuged at
14,000 × g for 30 min in Nanosep 300K Centrifugal Devices (Pall, OD300C33) or
3K Amicon Ultra-0.5 ml Centrifugal Filters (Millipore, UFC500324). The filtrate
was collected and the retentate extracted by centrifugation at 1000 × g for 2 min.
Volumes were adjusted with PBS to the original SP volumes.
EV isolation: EVs were isolated using Ultrafree-MC, DV 0.65 μm (Millipore,
UFC30DV0S) and GV 0.22 μm (Millipore, UFC30GV0S) centrifugal filter units as
described64. SP was centrifuged in the 0.65 μm filter unit for 20 min at 1000 × g, the
filtrate was transferred to the 0.22 μm filter unit, and the procedure was repeated.
The final filtrate contains the vesicles <220 nm. The two retentates were combined
and diluted to the original SP volume and contain the vesicles >220 nm.
Nanoparticle tracking analysis. Videos of EVs derived from SP, urine, and saliva
diluted in PBS were recorded for 60 s in a NanoSight LM10 and size distribution
was evaluated by the NanoSight NTA software. Between the samples, the chamber
was washed thoroughly and PBS was used to confirm absence of contaminating
particles.
Transmission electron microscopy. Samples were adsorbed on glow discharged
carbon-coated copper grids (Electric glow discharger Edwards High Vacuum) for
1 min at room temperature. Next, the grids were washed 3 times for 3 s in distilled
H2O and negatively stained with 2% (w/v) uranyl acetate in H2O by another three
incubation periods of 3 s. Excess solution was removed by filter paper and samples
were allowed to dry. Samples were imaged with a JEOL JEM1400 transmission
electron microscope at an accelerating voltage of 120 kV.
Influence of SE on infection of VT blocks. VT and ET preparation and infection
was performed similar to HIV-1 cervical tissue explant studies52,53. Tissues were
cut into 2 × 2 × 1mm3 tissue blocks. Blocks were incubated with ZIKV GWUH and
25% SE or 25% PBS in a 15 ml falcon for 90 min. Blocks were then washed with
PBS and transferred into separate 96 wells containing 200 μl ECM culture medium.
In all, 100 μl supernatant was collected immediately (wash control, day 0) or at
consecutive days, stored at −80 °C, and analyzed by qPCR for viral RNA copy
numbers.
Statistical analyses. One-way ANOVA followed by Bonferroni’s multiple com-
parison test (*P < 0.01, **P < 0.001, ***P < 0.0001), two-way RM ANOVA followed
by Tukey’s multiple comparison test (*P < 0.05, **P < 0.01, ***P < 0.001), and
Friedman test was performed using GraphPad Prism version 7.03 for Windows,
GraphPad Software, La Jolla, CA, USA, www.graphpad.com. Absence of sig-
nificance (ns: not significant) was only indicated when relevant.
Data availability. All relevant data are available from the authors.
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